Hamilton families have one last chance to get their babies immunized against a common virus that can cause serious lung infections before a clinic at McMaster Children’s Hospital closes. The last ...
Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...
More than 2 years after the child was born, no identifiable features of SMA have been observed, reported Richard Finkel, MD, of St. Jude Children's Research Hospital in Memphis, Tennessee, and ...
A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...
High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...
Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.
Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...
SK bioscience announced on the 14th that it has begun supplying the antibody injection for respiratory syncytial virus (RSV) prevention called "Beyfortus" from the French company Sanofi. Beyfortus can ...
We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other international ...
This was propelled by blockbuster asthma drug Dupixent (dupilumab) and new launches such as respiratory syncytial virus (RSV) preventative antibody Beyfortus (nirsevimab), developed in partnership ...
AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% ...
AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% year over ...